Document Detail


Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects.
MedLine Citation:
PMID:  20635904     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hematopoietic stem cell transplantation (HSCT) is a particularly important treatment for hematologic malignancies. Unfortunately, following allogeneic HSCT, graft-versus-host disease, immunosuppression and susceptibility to opportunistic infections remain among the most substantial problems restricting the efficacy and use of this procedure, particularly for cancer. Adoptive immunotherapy and/or manipulation of the graft offer ways to attack residual cancer as well as other transplant-related complications. Recent exciting discoveries have demonstrated that HSCT could be expanded to solid tissue cancers with profound effects on the effectiveness of adoptive immunotherapy. This review will provide a background regarding HSCT, discuss the complications that make it such a complex treatment procedure following up with current immunotherapeutic strategies and discuss emerging approaches in applying immunotherapy in HSCT for cancer.
Authors:
Myriam N Bouchlaka; Doug Redelman; William J Murphy
Related Documents :
16111464 - Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines.
23046034 - Landmarks in prostate cancer screening.
74354 - Retroviruses and cancer.
18259184 - Interleukin 21: combination strategies for cancer therapy.
23166824 - Hyaluronan (ha) interacting proteins rhamm and hyaluronidase impact prostate cancer cel...
7667564 - A proportional regression model for 20 year survival of colon cancer in norway.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Immunotherapy     Volume:  2     ISSN:  1750-7448     ISO Abbreviation:  Immunotherapy     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-07-19     Completed Date:  2010-10-29     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  101485158     Medline TA:  Immunotherapy     Country:  England    
Other Details:
Languages:  eng     Pagination:  399-418     Citation Subset:  IM    
Affiliation:
Department of Microbiology & Immunology, University of Nevada, Reno, NV, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Combined Modality Therapy
Disease Models, Animal
Graft vs Host Disease / immunology,  prevention & control*
Graft vs Tumor Effect / immunology
Hematopoietic Stem Cell Transplantation / methods*
Humans
Immunotherapy, Adoptive / methods*
Neoplasms / immunology,  therapy*
Treatment Outcome
Grant Support
ID/Acronym/Agency:
R01 CA095572-09/CA/NCI NIH HHS; R01 CA102282-09/CA/NCI NIH HHS
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Present state of target therapy for disseminated renal cell carcinoma.
Next Document:  Acknowledgements.